Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen

Cancer Research

Volumn 68, Issue 2, 2008, Pages 415-424

  Amundson, Sally A ^a,b   Do, Khanh T ^b   Vinikoor, Lisa C ^b   Lee, R Anthony ^b   Koch Paiz, Christine A ^b   Ahn, Jaeyong ^a   Reimers, Mark ^b,c   Chen, Yidong ^b   Scudiero, Dominic A ^d   Weinstein, John N ^b   Trent, Jeffrey M ^e   Bittner, Michael L ^e   Meltzer, Paul S ^b   Fornace Jr , Albert J ^a,f  

^a NewYork Presbyterian Hospital   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d SAIC FREDERICK INC   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; DATA BASE; GAMMA RADIATION; GENE EXPRESSION; GENOTOXICITY; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOBLASTOID CELL LINE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; CELL PROLIFERATION; CLUSTER ANALYSIS; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MITOSIS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UNITED STATES;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, P53; HUMANS; MITOSIS; NATIONAL CANCER INSTITUTE (U.S.); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; UNITED STATES;

EID: 39049106219     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2120     Document Type: Article

References (45)

1. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
2. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
3. Weinstein JN. Spotlight on molecular profiling: "integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 2006;5:2601-5.
4. Weinstein JN, Myers TG, O'Connor PM, et al. An information intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
5. Bae I, Smith ML, Sheikh MS, et al. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res 1996;56:840-7.
6. Carrier F, Georgel PT, Pourquier P, et al. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol 1999;19:1673-85.
7. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ, Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
8. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
9. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
10. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
11. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98:10787-92.
12. Annereau JP, Szakacs G, Tucker CJ, et al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 2004;66:1397-405.
13. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
14. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32.
15. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
16. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67.
17. Amundson SA, Do KT, Fornace AJ, Jr. Induction of stress genes by low doses of γ rays. Radiat Res 1999;152:225-31.
18. Amundson SA, Bittner M, Chen YD, Trent J, Meltzer P, Fornace AJ, Jr. cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogene 1999;18:3666-72.
19. Amundson SA, Patterson A, Do KT, Fornace AJ. A nucleotide excision repair master-switch: p53 regulated coordinate induction of global genomic repair genes. Cancer Biol Ther 2002;1:145-9.
20. Amundson SA, Lee RA, Koch-Paiz CA, et al. Differential responses of stress genes to low dose-rate γ irradiation. Mol Cancer Res 2003;1:445-52.
21. Koch-Paiz CA, Amundson SA, Bittner ML, Meltzer PS, Fornace AJ, Jr. Functional genomics of UV radiation responses in human cells. Mutat Res 2004;549:65-78.
22. Amundson SA, Do KT, Vinikoor L, et al. Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 2005;24:4572-9.
23. Amundson SA, Shahab S, Bittner M, Meltzer P, Trent J, Fornace AJ, Jr. Identification of potential mRNA markers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat Res 2000;154:342-6.
24. Amundson SA, Grace MB, McLeland CB, et al. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res 2004;64:6368-71.
25. Stinson SF, Alley MC, Kopp WC, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992;12:1035-53.
26. Furth EE, Thilly WG, Penman BW, Liber HL, Rand WM. Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates. Anal Biochem 1981;110:1-8.
27. Chen Y, Dougherty ER, Bittner ML. Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt 1997;2:364-74.
28. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, Trent JM. Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 2002;18:1207-15.
29. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
30. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
31. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
32. Koch-Paiz CA, Momenan R, Amundson SA, Lamoreaux E, Fornace AJ, Jr. Estimation of relative mRNA content by filter hybridization to a polyuridylic probe. Biotechniques 2000;29:708-14.
33. Chuang YY, Chen Q, Brown JP, Sedivy JM, Liber HL. Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res 1999;59:3073-6.
34. Hall EJ. Radiobiology for the radiologist. 5th edition. Philadelphia: Lippincott Williams and Wilkins; 2000.
35. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
36. Hosack DA, Dennis GJ, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
37. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
38. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 2005;24:6090-100.
39. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004;23:237-57.
40. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000;14:804-16.
41. Ma Y, Freeman SN, Cress WD. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biol Ther 2004;3:1262-9.
42. DuPree EL, Mazumder S, Almasan A. Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res 2004;64:4390-3.
43. 2 arrest response to genotoxic stress in prostate carcinoma. Oncogene 2007;26:1897-909.
44. Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA. E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol 1997;17:7268-82.
45. Torres-Roca JF, Eschrich S, Zhao H, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005;65:7169-76.